vTv Therapeutics Enters Second Amendment to License Agreement with Newsoara Biopharma
Feb 02, 2026
Contract Type
licensing
High PointBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma
Description
On January 30, 2026, vTv Therapeutics LLC entered into the Second Amendment to a License Agreement with Newsoara Biopharma Co., Ltd. This amendment expands Newsoara's rights to vTv's PDE4 inhibitor, HPP737, to include all countries globally upon payment of a $20 million upfront fee. Additionally, Newsoara is obligated to pay up to $50 million in development milestones and $65 million in sales-related payments.
Company Information
Company
vTv Therapeutics Inc.
Location
4170 MENDENHALL OAKS PKWY
High Point, North Carolina, United States
About
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, and glioblastoma and other cancers and cancer treatment-related conditions.
High PointBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma